Currently Recruiting

Other Active Trials

Past Findings

D-5 (ELND0005)

A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging, Safety, and Efficacy Study of Oral ELND005 (AZD-103) in Alzheimer's Disease

Status:	Active, Not Recruiting
Eligible Population(s):	Alzheimer's Disease
GCO Number:	08-0449 IRB approved through 06/30/2009
Principal Investigator:	Corbett Schimming, MD
Study Coordinator:	Andrew Vigario

A new phase II study is being conducted in the US and Canada to evaluate the safety and effectiveness of an experiemntal drug known as ELND005, or scyllo-inositol, for the potential treatment of Alzheimer's disease (AD). ELND005 is one of the many cutting edge disease-modifying agents that are being tested to determine if it can reduce the progression of AD by breaking down the build-up of amyloid plaques in the duration of the study. All participants will be carefully monitored at the research clinic throughout the study.

Current participants:

• are between 50-85 years of age
• have a diagnosis of probable AD
• have a Mini-Mental Status Exam of 16-26 inclusive
• have a magnetic resonance imaging (MRI) scan consistent with AD diagnosis
• have a caregiver who is able to attend all study visits

This study is closed to enrollment.